• Markets
    • icon
  • Companies
ACW · ASX

Actinogen Medical Limited (ASX:ACW)

AU$0.025

 0.0 (0.0%)
ASX:Live
01/12/2023 04:10:47 PM
HALO Ords HALO Earnings Momentum HALO Capital Efficiency GROWTH AUS All-Consensus +1
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

ACW Overview

ACW Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About ACW

Website

Actinogen Medical Limited

Telephone

61.2.8964.7401

Address

Level 9 Suite 901 109 Pitt Street Sydney, New South Wales (NSW) 2000

Description

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company was founded by Geoff E. D. Brooke & David Keast on March 23, 1999 and is headquartered in Sydney, Australia.

ACW Price Chart

Key Stats

Market Cap

AU$54.10M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.01 - 0.12

Trade Value (12mth)

AU$12,182.00

1 week

8.7%

1 month

38.89%

YTD

-73.17%

1 year

-77.37%

All time high

0.853592

Key Fundamentals

EPS 3 yr Growth

21.300%

EBITDA Margin

N/A

Operating Cashflow

-$9m

Free Cash Flow Return

-49.40%

ROIC

-61.00%

Interest Coverage

-931.80

Quick Ratio

7.00

Other Data

Shares on Issue (Fully Dilluted)

1891m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ACW Announcements

Latest Announcements

Date Announcements

31 May 18

Actinogen Medical to present at BIO International 2018

×

Actinogen Medical to present at BIO International 2018

31 March 23

Actinogen CMO presents at ADPD 2023 conference

×

Actinogen CMO presents at ADPD 2023 conference

31 July 23

Trading Halt

×

Trading Halt

31 July 23

Quarterly Activity Report & Appendix 4C

×

Quarterly Activity Report & Appendix 4C

31 August 23

Prof Paul Maruff & Dr Dana Hilt webinar & slide deck

×

Prof Paul Maruff & Dr Dana Hilt webinar & slide deck

30 November 16

CEO's Presentation to AGM

×

CEO's Presentation to AGM

30 November 16

Results of Annual General Meeting

×

Results of Annual General Meeting

30 November 10

Annual General Meeting Presentation

×

Annual General Meeting Presentation

30 January 23

Quarterly Activity Report & Appendix 4C

×

Quarterly Activity Report & Appendix 4C

30 August 23

ACW appoints company for rights issue shareholder contact

×

ACW appoints company for rights issue shareholder contact

30 August 23

ACW secures further $0.5m rights issue shortfall commitment

×

ACW secures further $0.5m rights issue shortfall commitment

30 August 23

ACW Appendix 4E and 2023 Annual Report

×

ACW Appendix 4E and 2023 Annual Report

30 August 23

Corporate Governance Statement

×

Corporate Governance Statement

30 August 23

Appendix 4G

×

Appendix 4G

30 August 23

Actinogen FY2023 results, following the science

×

Actinogen FY2023 results, following the science

30 August 21

Appendix 4E & Annual Report

×

Appendix 4E & Annual Report

29 September 23

ACW presents to the Asian Society Against Dementia congress

×

ACW presents to the Asian Society Against Dementia congress

29 November 17

Chairman's Annual General Meeting Address

×

Chairman's Annual General Meeting Address

29 November 17

Managing Director's Annual General Meeting Presentation

×

Managing Director's Annual General Meeting Presentation

29 November 17

Results of Annual General & Special General Meetings

×

Results of Annual General & Special General Meetings

29 November 12

Results of Annual General Meeting

×

Results of Annual General Meeting

29 August 23

Prof Paul Maruff on neuroscience drug development & Xanamem

×

Prof Paul Maruff on neuroscience drug development & Xanamem

29 April 20

Actinogen Presentation at AAT-ADPD International Congress

×

Actinogen Presentation at AAT-ADPD International Congress

28 September 22

Date of AGM and Closing Date for Director Nominations

×

Date of AGM and Closing Date for Director Nominations

28 September 18

Notification of 2018 Annual General Meeting Date

×

Notification of 2018 Annual General Meeting Date

28 October 22

Quarterly Activity Report & Appendix 4C

×

Quarterly Activity Report & Appendix 4C

28 October 13

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

ACW Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.00 -0.01 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.00 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 40.4 -96.4 -3.6 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.00 -0.01 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 53.0 -123.3 -7.2 Lock Lock Lock
     Yield % Lock Lock Lock Lock -0.9 -11.1 -12.1 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.01 0.01 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.01 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 31.2 21.9 -45.1 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 1,405 1,717 1,876 Lock Lock Lock
Basic m Lock Lock Lock Lock 1,405 1,717 1,876 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 6 13 15 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 6.4 -3.6 -1.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -6 -13 -15 Lock Lock Lock
     Growth % Lock Lock Lock Lock 35.1 -131.5 -21.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -6 -13 -16 Lock Lock Lock
     Growth % Lock Lock Lock Lock 33.8 -123.1 -20.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -6 -13 -16 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -2 -4 -5 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -4 -9 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock 26.6 -142.6 -13.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -2 -10 -9 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 10 12 1 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -2 -10 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock 39.9 -450.3 8.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 13 16 8 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 18 23 15 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -13 -16 -8 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 2 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 17 22 13 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 18 22 13 Lock Lock Lock
     Growth % Lock Lock Lock Lock 57.5 23.9 -38.6 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -21.3 -40.8 -70.7 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -22.4 -43.7 -80.2 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -40.8 -66.5 -89.7 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -27.2 -48.1 -61.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -12.0 -48.2 -49.4 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -247.2 -691.2 -931.8 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 2.4 1.3 0.5 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -75.5 -74.5 -62.5 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 19.9 13.8 7.0 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 19.9 13.8 7.0 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 89.1 80.2 66.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -228.3 -643.2 -482.8 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -21.3 -40.8 -70.7 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -22.4 -43.7 -80.2 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -22.4 -43.7 -80.2 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 207.2 588.0 899.9 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -207.2 -588.0 -899.9 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ACW Shortsell

Frequently Asked Questions

The current share price of Actinogen Medical Limited (ACW:ASX) is AU$0.025.
The 52-week high share price for Actinogen Medical Limited (ACW:ASX) is AU$0.12.
The 52-week low share price for Actinogen Medical Limited (ACW:ASX)? is AU$0.01.
Actinogen Medical Limited (ACW:ASX) does not pay a dividend.
Actinogen Medical Limited (ACW:ASX) does not pay a dividend.
Actinogen Medical Limited (ACW:ASX) has a franking level of 0%.
Actinogen Medical Limited (ACW:ASX) is classified in the Healthcare.
The current P/E ratio for Actinogen Medical Limited (ACW:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.